Interleukin-33 (IL-33) emerges as a pivotal, context-dependent neuroimmune regulator and precision therapeutic target in diverse CNS disorders
Background
The central nervous system (CNS) is highly susceptible to neuroinflammation, a critical driver in numerous neurological disorders. Current therapeutic strategies often lack precision, failing to adequately address the complex interplay between immune cells and neuronal function. Interleukin-33 (IL-33), an alarmin cytokine of the IL-1 family, has been identified as a crucial mediator of neuroimmune interactions, acting through its receptor ST2. Understanding its context-dependent roles in conditions like epilepsy, stroke, Alzheimer's disease (AD), and multiple sclerosis (MS) is vital for developing targeted immunomodulatory treatments.
Study Design
This review synthesizes current understanding of Interleukin-33 (IL-33) in central nervous system (CNS) disorders, analyzing its cellular mechanisms and therapeutic implications. It examines existing literature detailing IL-33's role across various neurological conditions, including epilepsy, stroke, traumatic brain injury (TBI), Parkinson's disease (PD), Alzheimer's disease (AD), multiple sclerosis (MS), cerebral malaria, and glioma. The authors focused on how IL-33 modulates microglial polarization, T cell differentiation, and other immune cell circuits, aiming to delineate its context-dependent protective and pathogenic effects.
Results
Across diverse neurological disorders, IL-33 exhibits both protective and pathogenic effects, contingent on the specific disease context and stage. It orchestrates immune responses by modulating microglial polarization, shaping T cell differentiation, activating type 2 innate lymphoid cells (ILC2s), and engaging mast cell-macrophage regulatory circuits. In epilepsy, IL-33 modulates neuroinflammation and neuronal excitability. For stroke, it attenuates acute neurovascular injury while influencing post-stroke remodeling. > In Alzheimer's disease (AD), IL-33 enhances amyloid-β clearance and mitigates chronic neuroinflammation, suggesting a protective role. Conversely, in multiple sclerosis (MS), IL-33 regulates autoimmune demyelination via T cell and innate immune pathways, highlighting its complex involvement. These shared yet disease-specific mechanisms underscore IL-33's central role in neuroimmune homeostasis.
Key Findings
- IL-33 acts as a pivotal alarmin cytokine regulating neuroimmune interactions in the CNS.
- IL-33 modulates microglial polarization, T cell differentiation, ILC2 activation, and mast cell-macrophage circuits.
- IL-33 exhibits both protective and pathogenic effects in a context-dependent manner across CNS disorders.
- In Alzheimer's disease, IL-33 enhances amyloid-β clearance and mitigates chronic neuroinflammation.
- In multiple sclerosis, IL-33 regulates autoimmune demyelination via T cell and innate immune pathways.
Why It Matters
This review significantly advances our understanding of IL-33 as a multifaceted regulator in CNS disorders, opening new avenues for precision neuroimmunology. For clinicians and researchers, it highlights IL-33's potential as a therapeutic target to modulate neuroinflammation and immune responses in a disease-specific manner. The findings suggest that future protocols might involve tailoring IL-33 modulation based on the specific neurological condition and its temporal stage, moving beyond broad anti-inflammatory approaches. Developing targeted IL-33 modulators could offer more effective treatments for conditions like AD, MS, and stroke, though significant research is still needed to define optimal timing and dosage for human translation.
il-33
neuroinflammation
cns-disorders
neuroimmunology
cytokine
alzheimers-disease